BioCryst gets $2.5 million
DURHAM – Durham-based BioCryst Pharmaceuticals Inc. will receive an additional $2.5 million for the development of a potential treatment for Marburg virus disease, which is a severe type of hemorrhagic fever caused by a virus in the same family as the Ebola virus.
The company announced the additional funding Monday. It follows $5 million it received in September from the National Institute of Allergy and Infectious Diseases. In total, the company could get $22 million across five years to get the treatment through Phase 1 trials.
“This is an important next step in moving the development program forward to an (investigational new drug) submission, leading to an initial safety trial in healthy human volunteers,” said Dr. William P. Sheridan, BioCryst’s chief medical officer, in a prepared statement in the announcement.
BioCryst works to design and develop small molecule drugs that block key enzymes involved in infectious and rare diseases. The company is also working on development of a treatment for influenza and for hereditary angioedema.